CANbridge Pharmaceuticals begins CAN103 phase 1/2 trial in Gaucher disease

CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease ... Read More